IGNYTA, INC.
SAN DIEGO, CA

At Ignyta, we fight cancer – not just one opponent but, rather, hundreds of different molecularly defined diseases that take away millions of lives every year. Our goal is not just to shrink tumors, but to eradicate residual disease – the source of cancer relapse and recurrence – in precisely defined patient populations by 2030. Our integrated “Rx/Dx” approach combines precision medicines (Rx) and in-house molecular diagnostics (Dx) for a distinct advantage in both identifying and targeting these hard-to-treat cancers in hard-to-find patients. We believe that Rx/Dx is what sets Ignyta apart in the journey toward a new future for cancer patients. From our founding in 2011, our goal at Ignyta has been to change lives by attacking the genomic causes of disease. Today, we focus exclusively on developing new precision therapeutics that fight the genomic causes of cancer. Learn more about what makes Ignyta different, including: “We are at a new and powerful moment in the fight against cancer. By shining a light on the genomic alterations responsible for cancer’s growth, we can now design innovative treatments specifically directed at the most relevant molecular targets and identify those patients who are most likely to benefit. Finally, cancer treatment has the potential to function the way we expect medicine to work: Ignyta is on the leading edge of this research, offering hope where, for so long, there has been only fear. At Ignyta, we work tirelessly on behalf of patients with cancer to offer potentially life-saving, precisely targeted therapeutics (Rx) guided by companion diagnostic (Dx) tests. Our integrated Rx/Dx strategy allows us to enter uncharted territory, illuminating the molecular drivers of cancer and quickly advancing treatments to address them. This approach embraces even those patients with the rarest cancers, who have the highest unmet need and who may otherwise not have access to effective treatment options. With our pipeline of potentially first-in-class and best-in-class precision medicines, we are pursuing the ultimate goal of not just shrinking tumors, but eradicating cancer relapse and recurrence in precisely defined patient populations. As certain as the sun rises every day, there are foundational principles that guide Ignyta: focusing with constancy on what is best for patients, pursuing high-quality science and data to help guide our decision making, conducting ourselves with uncompromising integrity and honesty, valuing positive teamwork in everything we do, and abiding by the Golden Rule. At Ignyta, we embrace people’s desire to live out their faith or moral convictions that drive them to excellence in what they do. We value bold action that generates tangible results. We look for high ingenuity, creativity, and energy in our people to do astonishing things. With such kinetics, we aspire to achieve greatness as a company. We desire to be a guiding biotechnology company in precision medicine – a leader who enlightens and sets a shining example for others. We seek to be a fun and energizing company that attracts the best and brightest people to come work with us, a partner of choice for pharmaceutical companies, and a recognized pioneer in precision medicine. We are passionate about working on superior products that improve patients’ lives, we are warmly loyal to each other and to those we work with (partners, collaborators) and for (patients, shareholders), and we are a company of self-starters seeking to be the best at what we do. We value ingenuity, hard work, and sustained persistence, translating into scientific breakthroughs and advancements in patient care. Like a well-oiled engine, we seek to communicate openly with each other in real time without barriers, invest in each other’s growth and development, remain adaptive to change without hesitation once the direction is set, be relentlessly data driven vs. ego driven, and pursue efficient productivity over busyness. We acknowledge that building a great company from scratch is difficult and that there are significant challenges along the way. The true test of character is the ability to meet adversity head on with grace, poise, and equanimity. We challenge the status quo; engage in healthy conflict; provide each other with timely, direct feedback; confront all facts and data – no matter how sobering; and use adversity to raise our game and emerge stronger. Our Product Focus We are relentlessly focused on products and making decisions based on sound scientific and business reasons. We seek to make healthcare advancements that benefit patients’ lives, not just to pursue interesting science for its own sake. At each stage, we ask ourselves whether our products will enable physicians and patients to make better informed decisions and a positive difference in patient care. 2014 – Ignyta presents landmark Trk inhibitor response at ASCO and achieves CLIA certification At ASCO 2014, Ignyta first presented evidence of Trk as a druggable target in oncology. In November of that year, Ignyta’s San Diego diagnostic laboratory passed the State of California survey for Clinical Laboratory Improvement Amendments (CLIA) certification, granting Ignyta permission to offer molecular diagnostic services to patients. This represented a milestone for Ignyta’s integrated Rx/Dx approach to serving cancer patients. 2015 – Ignyta puts entrectinib on the map at ASCO and launches STARTRK-2 At ASCO 2015, Ignyta presented Phase I clinical trial data for entrectinib, demonstrating that the drug candidate was well tolerated with no drug-related serious adverse events. A recommended Phase 2 dose was determined, and a 91% response rate in patients’ meeting expected Phase 2 eligibility criteria was observed. Ignyta initiated the Mr. Z was subsequently enrolled in Ignyta’s STARTRK clinical trial of entrectinib, and the results were dramatic. Visit the page to read Mr. Z’s amazing story, and the stories of other patients Ignyta has had the honor to treat in our clinical trials.